id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-0625-0007,FDA,FDA-2016-E-0625,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2017-09-20T04:00:00Z,2017,9,2017-09-20T04:00:00Z,,2017-09-20T18:14:20Z,,0,0,0900006482b64412
FDA-2016-E-0625-0006,FDA,FDA-2016-E-0625,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-12-13T05:00:00Z,2016,12,2016-12-13T05:00:00Z,,2016-12-13T16:22:40Z,,0,0,090000648240138b
FDA-2016-E-0625-0005,FDA,FDA-2016-E-0625,Determinations of Regulatory Review Periods for Purposes of Patent Extensions: NUCALA,Notice,Determinations,2016-12-13T05:00:00Z,2016,12,2016-12-13T05:00:00Z,2017-06-13T03:59:59Z,2016-12-13T14:24:15Z,2016-29838,0,0,09000064823fe725
FDA-2016-E-0625-0004,FDA,FDA-2016-E-0625,Letter from the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2016-10-13T04:00:00Z,2016,10,2016-10-13T04:00:00Z,,2016-10-13T14:58:19Z,,0,0,09000064822eb5cc
FDA-2016-E-0625-0003,FDA,FDA-2016-E-0625,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-05-11T04:00:00Z,2016,5,2016-05-11T04:00:00Z,,2016-05-11T16:01:29Z,,0,0,0900006481fc4521
FDA-2016-E-0625-0002,FDA,FDA-2016-E-0625,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-02-24T05:00:00Z,2016,2,2016-02-24T05:00:00Z,,2016-02-24T21:15:32Z,,0,0,0900006481e78f37
FDA-2016-E-0625-0001,FDA,FDA-2016-E-0625,Patent Extension Application from GlaxoSmithKline LLC,Other,Application,2016-02-24T05:00:00Z,2016,2,2016-02-24T05:00:00Z,,2024-01-22T15:53:12Z,,0,0,0900006481e78e29